GSK
2 years ago ⋅ English ⋅ 4 min read
Newsroom
US Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices votes to recommend Arexvy for the prevention of RSV disease in adults aged 60 and older with shared clinical decision making

For media and investors only- Launch is planned in the US before the 2023 RSV season- Committee recommendations mean over 55 million older adults in the US could have access to RSV vacc... Read More
GSK
2 years ago ⋅ English ⋅ 4 min read
Newsroom
GSK shares positive data for Arexvy, its respiratory syncytial virus (RSV) older adult vaccine, indicating protection over two RSV seasons

For media and investors only- New results from the ongoing AReSVi-006 phase III trial show vaccine efficacy against RSV-lower respiratory tract disease and severe disease over two full... Read More
GSK
2 years ago ⋅ English ⋅ 1 min read
Newsroom
GSK announces extension of FDA review period for momelotinib

For media and investors onlyGSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has extended the review period of the new drug application (NDA) for m... Read More
GSK
2 years ago ⋅ English ⋅ 5 min read
Newsroom
European Commission authorises GSK’s Arexvy, the first respiratory syncytial virus (RSV) vaccine for older adults

For media and investors only- Authorisation will help protect adults 60 years of age and older in 30 European countries* from RSV disease for the first time- In Europe, RSV leads to ove... Read More
GSK
2 years ago ⋅ English ⋅ 5 min read
Newsroom
GSK receives US FDA file acceptance for Jemperli (dostarlimab) plus chemotherapy for the treatment of dMMR/MSI-H primary advanced or recurrent endometrial cancer

For media and investors only- Submission accepted for Priority Review- Breakthrough Therapy designation granted for this potential indication- Application being reviewed under the FDA P... Read More
GSK
2 years ago ⋅ English ⋅ 5 min read
Newsroom
GSK presents pivotal data at ESPID confirming effectiveness of its 5-in-1 meningococcal ABCWY vaccine candidate, with demonstrated coverage against a panel of 110 MenB strains

For media and investors only- Preliminary results from phase III trial show all primary endpoints met, demonstrating statistical non-inferiority compared to Bexsero (meningococcal group... Read More